{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:54:53Z","timestamp":1790934893902,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003976","name":"Israel National Institute for Health Policy Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003976","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.bpobgyn.2020.02.007","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T11:36:24Z","timestamp":1583148984000},"page":"139-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Population-based genetic testing for Women's cancer prevention"],"prefix":"10.1016","volume":"65","author":[{"given":"Olivia","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Gaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Manchanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.bpobgyn.2020.02.007_bib1","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2020.02.007_bib2","author":"UK CR"},{"issue":"10","key":"10.1016\/j.bpobgyn.2020.02.007_bib3","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41436-019-0536-8","article-title":"The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis","volume":"21","author":"Ryan","year":"2019","journal-title":"Genet Med"},{"issue":"44","key":"10.1016\/j.bpobgyn.2020.02.007_bib4","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.02.007_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11154-007-9038-0","article-title":"Genetic susceptibility to breast cancer","volume":"8","author":"Bradbury","year":"2007","journal-title":"Rev Endocr Metab Disord"},{"issue":"10","key":"10.1016\/j.bpobgyn.2020.02.007_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186043","article-title":"Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1)","volume":"12","author":"Harter","year":"2017","journal-title":"PloS One"},{"issue":"34","key":"10.1016\/j.bpobgyn.2020.02.007_bib7","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2017.73.6314","article-title":"National estimates of genetic testing in women with a history of breast or ovarian cancer","volume":"35","author":"Childers","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.bpobgyn.2020.02.007_bib8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9809","key":"10.1016\/j.bpobgyn.2020.02.007_bib9","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/S0140-6736(11)61049-0","article-title":"Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial","volume":"378","author":"Burn","year":"2011","journal-title":"Lancet (London, England)"},{"issue":"12","key":"10.1016\/j.bpobgyn.2020.02.007_bib10","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/cancers10120524","article-title":"BRCA Mutations and Breast cancer prevention","volume":"10","author":"Kotsopoulos","year":"2018","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.bpobgyn.2020.02.007_bib11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA, J Am Med Assoc"},{"key":"10.1016\/j.bpobgyn.2020.02.007_bib12","article-title":"Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer","year":"2013"},{"issue":"9","key":"10.1016\/j.bpobgyn.2020.02.007_bib13","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/sj.bjc.6601792","article-title":"Cancer genetics services: a systematic review of the economic evidence and issues","volume":"90","author":"Griffith","year":"2004","journal-title":"Br J Canc"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.02.007_bib14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12889-017-4375-8","article-title":"Awareness, knowledge, perceptions, and attitudes towards genetic testing for cancer risk among ethnic minority groups: a systematic review","volume":"17","author":"Hann","year":"2017","journal-title":"BMC Publ Health"},{"issue":"14","key":"10.1016\/j.bpobgyn.2020.02.007_bib15","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.293.14.1729","article-title":"Racial differences in the use of BRCA1\/2 testing among women with a family history of breast or ovarian cancer","volume":"293","author":"Armstrong","year":"2005","journal-title":"J\u00a0Am Med Assoc"},{"issue":"6","key":"10.1016\/j.bpobgyn.2020.02.007_bib16","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/jamaoncol.2018.0340","article-title":"National distribution of cancer genetic testing in the United States: evidence for a gender disparity in hereditary breast and ovarian cancer","volume":"4","author":"Childers","year":"2018","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.bpobgyn.2020.02.007_bib17","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41431-019-0424-3","article-title":"Trends in BRCA testing and socioeconomic deprivation","volume":"27","author":"Martin","year":"2019","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"10.1016\/j.bpobgyn.2020.02.007_bib18","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/1471-0528.15654","article-title":"Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study","volume":"126","author":"Manchanda","year":"2019","journal-title":"Bjog"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.02.007_bib19","first-page":"72","article-title":"Perceptions of genetic testing for cancer predisposition among Ashkenazi Jewish women","volume":"10","author":"Lewis","year":"2007","journal-title":"Community Genet"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.02.007_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2009.25.0712","article-title":"Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women","volume":"28","author":"Metcalfe","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.bpobgyn.2020.02.007_bib21","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/onc.2015.181","article-title":"Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations","volume":"35","author":"Golmard","year":"2016","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.bpobgyn.2020.02.007_bib22","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/jmedgenet-2011-100082","article-title":"Determining the frequency of de novo germline mutations in DNA mismatch repair genes","volume":"48","author":"Win","year":"2011","journal-title":"J\u00a0Med Genet"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.02.007_bib23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jnci\/dju379","article-title":"Population testing for cancer predisposing BRCA1\/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial","volume":"107","author":"Manchanda","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.bpobgyn.2020.02.007_bib24","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2007.04.023","article-title":"Genetic epidemiology of BRCA mutations-family history detects less than 50% of the mutation carriers","volume":"43","author":"Moller","year":"2007","journal-title":"Eur J Canc"},{"issue":"39","key":"10.1016\/j.bpobgyn.2020.02.007_bib25","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.1073\/pnas.1415979111","article-title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","volume":"111","author":"Gabai-Kapara","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.bpobgyn.2020.02.007_bib26","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/sj.bjc.6604305","article-title":"The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions","volume":"98","author":"Antoniou","year":"2008","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.bpobgyn.2020.02.007_bib27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/jmg.2009.067850","article-title":"Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing","volume":"46","author":"Evans","year":"2009","journal-title":"J\u00a0Med Genet"},{"issue":"8","key":"10.1016\/j.bpobgyn.2020.02.007_bib28","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1158\/1055-9965.EPI-13-1364","article-title":"Recent BRCAPRO upgrades significantly improve calibration","volume":"23","author":"Mazzola","year":"2014","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"10","key":"10.1016\/j.bpobgyn.2020.02.007_bib29","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/jmedgenet-2017-104584","article-title":"Pathology update to the Manchester Scoring System based on testing in over 4000 families","volume":"54","author":"Evans","year":"2017","journal-title":"J\u00a0Med Genet"},{"issue":"8","key":"10.1016\/j.bpobgyn.2020.02.007_bib30","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","article-title":"BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors","volume":"21","author":"Lee","year":"2019","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.bpobgyn.2020.02.007_bib31","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jmedgenet-2017-105195","article-title":"Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population","volume":"55","author":"Manchanda","year":"2018","journal-title":"J\u00a0Med Genet"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.02.007_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1940-6207.CAPR-10-0345","article-title":"The search for unaffected individuals with Lynch syndrome: do the ends justify the means?","volume":"4","author":"Hampel","year":"2011","journal-title":"Canc Prev Res"},{"issue":"6","key":"10.1016\/j.bpobgyn.2020.02.007_bib33","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.cgh.2010.03.010","article-title":"Underdiagnosis of Lynch syndrome involves more than family history criteria","volume":"8","author":"Singh","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpobgyn.2020.02.007_bib34","author":"UK"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.02.007_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1056\/NEJMra013182","article-title":"Population screening in the age of genomic medicine","volume":"348","author":"Khoury","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2020.02.007_bib36","author":"Burke"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.02.007_bib37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2217\/fon.15.278","article-title":"Genetic screening for gynecological cancer: where are we heading?","volume":"12","author":"Manchanda","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.bpobgyn.2020.02.007_bib38","series-title":"ACCE model process for evaluating genetic tests. Genomic Testing","author":"CDC","year":"2010"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.02.007_bib39","first-page":"1085","article-title":"Screening for 185delAG in the ashkenazim","volume":"60","author":"Richards","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.02.007_bib40","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/1471-0528.15905","article-title":"Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes","volume":"127","author":"Manchanda","year":"2020","journal-title":"BJOG"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.02.007_bib41","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3747\/co.24.3828","article-title":"Coming of age in Canada: a study of population-based genetic testing for breast and ovarian cancer","volume":"24","author":"Akbari","year":"2017","journal-title":"Curr Oncol"},{"key":"10.1016\/j.bpobgyn.2020.02.007_bib42","series-title":"Predicting risk of ovarian malignancy improved screening and early detection feasibility study","year":"2017"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.02.007_bib43","first-page":"678","article-title":"Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium","volume":"52","author":"Easton","year":"1993","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.02.007_bib44","first-page":"265","article-title":"Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast cancer linkage consortium","volume":"56","author":"Easton","year":"1995","journal-title":"Am J Hum Genet"},{"issue":"23","key":"10.1016\/j.bpobgyn.2020.02.007_bib45","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"J\u00a0Am Med Assoc"},{"issue":"7","key":"10.1016\/j.bpobgyn.2020.02.007_bib46","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/gutjnl-2017-314057","article-title":"Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch syndrome database","volume":"67","author":"Moller","year":"2018","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.02.007_bib47","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ng.2224","article-title":"Germline RAD51C mutations confer susceptibility to ovarian cancer","volume":"44","author":"Loveday","year":"2012","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.bpobgyn.2020.02.007_bib48","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ng.893","article-title":"Germline mutations in RAD51D confer susceptibility to ovarian cancer","volume":"43","author":"Loveday","year":"2011","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.bpobgyn.2020.02.007_bib49","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv214","article-title":"Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer","volume":"107","author":"Ramus","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bpobgyn.2020.02.007_bib50","first-page":"JCO1901907","article-title":"Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families","author":"Yang","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.bpobgyn.2020.02.007_bib51","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.bpobgyn.2020.02.007_bib52","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.30498","article-title":"A\u00a0study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes","volume":"123","author":"Buys","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.02.007_bib53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM200107263450401","article-title":"Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation","volume":"345","author":"Modan","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.02.007_bib54","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1086\/302853","article-title":"BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer","volume":"66","author":"Moslehi","year":"2000","journal-title":"Am J Hum Genet"},{"issue":"5645","key":"10.1016\/j.bpobgyn.2020.02.007_bib55","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.02.007_bib56","first-page":"1","article-title":"Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women","author":"Kurian","year":"2017","journal-title":"JCO Precision Oncol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.02.007_bib57","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2017.08.030","article-title":"Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls","volume":"147","author":"Lilyquist","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.bpobgyn.2020.02.007_bib58","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/jmedgenet-2015-103077","article-title":"A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects","volume":"52","author":"Jervis","year":"2015","journal-title":"J\u00a0Med Genet"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.02.007_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.2140","article-title":"Exome sequencing-based screening for BRCA1\/2 expected pathogenic variants among adult biobank participants","volume":"1","author":"Manickam","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.02.007_bib60","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10689-013-9611-5","article-title":"How do we approach the goal of identifying everybody with Lynch Syndrome?","volume":"12","author":"Hampel","year":"2013","journal-title":"Fam Cancer"},{"issue":"20","key":"10.1016\/j.bpobgyn.2020.02.007_bib61","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","article-title":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews","volume":"336","author":"Struewing","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.02.007_bib62","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","article-title":"Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2","volume":"14","author":"Roa","year":"1996","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.02.007_bib63","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/302320","article-title":"The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews","volume":"64","author":"Hartge","year":"1999","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.02.007_bib64","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10549-006-9261-5","article-title":"Direct-to-patient BRCA1 testing: the twoj Styl experience","volume":"100","author":"Gronwald","year":"2006","journal-title":"Breast Canc Res Treat"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.02.007_bib65","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/bjc.2013.309","article-title":"A\u00a0comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing","volume":"109","author":"Metcalfe","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bpobgyn.2020.02.007_bib66","doi-asserted-by":"crossref","first-page":"29506","DOI":"10.1038\/srep29506","article-title":"Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients","volume":"6","author":"George","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.bpobgyn.2020.02.007_bib67","doi-asserted-by":"crossref","first-page":"568","DOI":"10.7861\/clinmedicine.17-6-568","article-title":"The use of panel testing in familial breast and ovarian cancer","volume":"17","author":"Prapa","year":"2017","journal-title":"Clin Med"},{"issue":"26","key":"10.1016\/j.bpobgyn.2020.02.007_bib69","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.2015.61.2408","article-title":"Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population","volume":"33","author":"Song","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.02.007_bib70","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41436-018-0277-0","article-title":"Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility","volume":"21","author":"Rowley","year":"2019","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.02.007_bib71","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.2007.53","article-title":"The emerging landscape of breast cancer susceptibility","volume":"40","author":"Stratton","year":"2008","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.02.007_bib72","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ng.569","article-title":"Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene","volume":"42","author":"Meindl","year":"2010","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.bpobgyn.2020.02.007_bib73","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.2013.51.3226","article-title":"Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer","volume":"32","author":"Schwartz","year":"2014","journal-title":"J\u00a0Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.bpobgyn.2020.02.007_bib74","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/jmedgenet-2015-103740","article-title":"Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1\/2 mutations","volume":"53","author":"Manchanda","year":"2016","journal-title":"J\u00a0Med Genet"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.02.007_bib75","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1399-0004.2010.01499.x","article-title":"Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2","volume":"78","author":"Metcalfe","year":"2010","journal-title":"Clin Genet"},{"key":"10.1016\/j.bpobgyn.2020.02.007_bib76","author":"Manchanda"},{"key":"10.1016\/j.bpobgyn.2020.02.007_bib77","article-title":"Online BRCA1\/2 screening in the Australian Jewish community: a qualitative study","author":"Yuen","year":"2019","journal-title":"J\u00a0Community Genet"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.02.007_bib78","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1471-0528.2011.03257.x","article-title":"Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis","volume":"119","author":"Manchanda","year":"2012","journal-title":"BJOG"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.02.007_bib79","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s10549-011-1941-0","article-title":"Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening","volume":"133","author":"Metcalfe","year":"2012","journal-title":"Breast Canc Res Treat"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.02.007_bib80","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","article-title":"International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation","volume":"121","author":"Metcalfe","year":"2019","journal-title":"Br J Canc"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.02.007_bib81","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1399-0004.2009.01329.x","article-title":"Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing","volume":"77","author":"Skytte","year":"2010","journal-title":"Clin Genet"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.02.007_bib82","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/igc.0000000000001147","article-title":"Setting the threshold for surgical prevention in women at increased risk of ovarian cancer","volume":"28","author":"Manchanda","year":"2018","journal-title":"Int J Gynecol Canc"},{"issue":"6","key":"10.1016\/j.bpobgyn.2020.02.007_bib83","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00125817-200011000-00001","article-title":"Mammography behavior after receiving a negative BRCA1 mutation test result in the Ashkenazim: a community-based study","volume":"2","author":"Plon","year":"2000","journal-title":"Genet Med"},{"key":"10.1016\/j.bpobgyn.2020.02.007_bib84","article-title":"Population screening for BRCA1\/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral","author":"Lieberman","year":"2016","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.02.007_bib85","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/01.GIM.0000162874.58370.C0","article-title":"Concerns in a primary care population about genetic discrimination by insurers","volume":"7","author":"Hall","year":"2005","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.02.007_bib86","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10689-016-9918-0","article-title":"Community attitudes towards a Jewish community BRCA1\/2 testing program","volume":"16","author":"Cousens","year":"2017","journal-title":"Fam Cancer"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.02.007_bib87","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00125817-200209000-00005","article-title":"A\u00a0population-based study of Ashkenazi Jewish women's attitudes toward genetic discrimination and BRCA1\/2 testing","volume":"4","author":"Lehmann","year":"2002","journal-title":"Genet Med"},{"issue":"28","key":"10.1016\/j.bpobgyn.2020.02.007_bib88","doi-asserted-by":"crossref","first-page":"12629","DOI":"10.1073\/pnas.1007983107","article-title":"Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing","volume":"107","author":"Walsh","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"28","key":"10.1016\/j.bpobgyn.2020.02.007_bib89","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1200\/JCO.2015.60.8596","article-title":"Population-wide screening for germline BRCA1 and BRCA2 mutations: too much of a good thing?","volume":"33","author":"Yurgelun","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.bpobgyn.2020.02.007_bib90","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1200\/JCO.2005.05.1656","article-title":"Genetics, epidemiology, and cancer disparities: is it black and white?","volume":"24","author":"Rebbeck","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.bpobgyn.2020.02.007_bib91","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2006.05.5889","article-title":"Disparities in genetic testing: thinking outside the BRCA box","volume":"24","author":"Hall","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.bpobgyn.2020.02.007_bib92","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/jama.2014.12483","article-title":"Population-based screening for BRCA1 and BRCA2: 2014 Lasker award","volume":"312","author":"King","year":"2014","journal-title":"J\u00a0Am Med Assoc"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.02.007_bib93","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jnci\/dju380","article-title":"Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing","volume":"107","author":"Manchanda","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.02.007_bib94","doi-asserted-by":"crossref","first-page":"578 e1","DOI":"10.1016\/j.ajog.2017.06.038","article-title":"Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry","volume":"217","author":"Manchanda","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.02.007_bib95","doi-asserted-by":"crossref","first-page":"431 e1","DOI":"10.1016\/j.ajog.2017.12.221","article-title":"Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women","volume":"218","author":"Patel","year":"2018","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.bpobgyn.2020.02.007_bib96","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/jnci\/djx265","article-title":"Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women","volume":"110","author":"Manchanda","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.bpobgyn.2020.02.007_bib97","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1038\/s41436-019-0581-3","article-title":"Response to Veenstra et\u00a0al","volume":"21","author":"Lacaze","year":"2019","journal-title":"Genet Med"},{"issue":"9","key":"10.1016\/j.bpobgyn.2020.02.007_bib98","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41436-019-0457-6","article-title":"Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis","volume":"21","author":"Zhang","year":"2019","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.02.007_bib99","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.3747\/co.22.2527","article-title":"Is it time to offer BRCA1 and BRCA2 testing to all Jewish women?","volume":"22","author":"Metcalfe","year":"2015","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.02.007_bib100","doi-asserted-by":"crossref","first-page":"8105","DOI":"10.1038\/s41598-018-26526-x","article-title":"Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma","volume":"8","author":"Takeuchi","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.02.007_bib101","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/aja.2011.150","article-title":"The role of BRCA1 and BRCA2 in prostate cancer","volume":"14","author":"Castro","year":"2012","journal-title":"Asian J Androl"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.02.007_bib102","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13058-016-0671-y","article-title":"Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1\/2","volume":"18","author":"Silvestri","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"10","key":"10.1016\/j.bpobgyn.2020.02.007_bib103","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/sj.bjc.6602207","article-title":"Psychosocial impact of breast\/ovarian (BRCA 1\/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort","volume":"91","author":"Watson","year":"2004","journal-title":"Br J Canc"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.02.007_bib104","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cancergencyto.2005.07.011","article-title":"Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families","volume":"165","author":"Lynch","year":"2006","journal-title":"Canc Genet Cytogenet"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.02.007_bib105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1040-8428(01)00141-X","article-title":"Ethical implications of genetic testing for breast cancer susceptibility","volume":"40","author":"Surbone","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6948","key":"10.1016\/j.bpobgyn.2020.02.007_bib106","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/bmj.309.6948.184","article-title":"Medical ethics: four principles plus attention to scope","volume":"309","author":"Gillon","year":"1994","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.bpobgyn.2020.02.007_bib107","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/medethics-2018-105229","article-title":"Familial genetic risks: how can we better navigate patient confidentiality and appropriate risk disclosure to relatives?","volume":"45","author":"Dove","year":"2019","journal-title":"J\u00a0Med Ethics"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.02.007_bib108","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv078","article-title":"Breast cancer prevention in the era of precision medicine","volume":"107","author":"Narod","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bpobgyn.2020.02.007_bib109","series-title":"Confidentiality: good practice in handling patient information","author":"Council","year":"2017"},{"issue":"6","key":"10.1016\/j.bpobgyn.2020.02.007_bib110","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/1471-0528.15657","article-title":"A\u00a0commentary on population genetic testing for primary prevention: changing landscape and the need to change paradigm","volume":"126","author":"Manchanda","year":"2019","journal-title":"BJOG"},{"issue":"6","key":"10.1016\/j.bpobgyn.2020.02.007_bib111","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/gim.2016.175","article-title":"Population screening for BRCA1\/BRCA2 mutations: lessons from qualitative analysis of the screening experience","volume":"19","author":"Lieberman","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.bpobgyn.2020.02.007_bib112","series-title":"My medical choice","author":"Jolie","year":"2013"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693420300341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693420300341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:11:26Z","timestamp":1761498686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693420300341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":111,"alternative-id":["S1521693420300341"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2020.02.007","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population-based genetic testing for Women's cancer prevention","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2020.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}